Dr. Philip Connell is an expert in radiotherapy with a particular focus on sarcomas, thoracic cancers, and pediatric malignancies.
In addition to his clinical responsibilities, Dr. Connell is an active cancer researcher. He received laboratory training in cancer biology through a National Cancer Institute fellowship. His oncology research program is working to identify molecular markers of treatment resistance, and to develop new anti-cancer agents that can overcome these molecular hurdles. His newest ongoing projects involve several novel, high-throughput assays designed to identify potential drugs that modify DNA repair. With these systems, researchers have the potential to discover new chemical compounds with wide-ranging impacts--from improving present oncology therapies to blocking the mutagenic effects of chemotherapy and radiotherapy.